Nodular Basal Cell Carcinoma Phase-One Trial
Scientia Clinical Research is recruiting adults (aged 18 to 85 years) with untreated nodular basal cell carcinoma to participate in a Phase 1/2a clinical trial. The study is evaluating FLD-103, a novel intralesional Hedgehog pathway inhibitor. This treatment may offer a less invasive alternative to surgery.
Researches from UNSW appreciate referrals of potentially eligible patients who are aged 18 to 85 years and have a diagnosis of untreated nodular basal cell carcinoma. Please contact the study coordinator from Scientia Clinical Research via email for more information: matthew.wong@scientiaclinicalresearch.com.au
Ethics: HREC approved on 07-Aug-2024 as Application 2024-06-773 (lead site), and on 09-Aug-2024 as Application 2024-06-773-AC (Scientia Clinical Research additional site).
Ageing Well Tool in general practice
Join Macquarie University in trialing the Ageing Well Tool, a screening and early intervention tool designed to identify and reduce risks for dementia and enhance overall wellbeing in primary care patients aged 60-70, to set them up for ageing well.
Click here for more information.